Survival

Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma

Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma

By

A retrospective study evaluated the relationship of BMI with survival outcomes among patients with metastatic melanoma who received targeted therapy, immunotherapy, or chemotherapy.

Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer

Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer

By

SPARTAN phase 3 study shows that apalutamide prolongs metastasis-free survival and time to symptomatic progression compared with placebo among men with nonmetastatic CRPC.

Antibiotics May Reduce Treatment-Related Issues in Renal Cell Carcinoma

Antibiotics May Reduce Treatment-Related Issues in Renal Cell Carcinoma

By

Researchers evaluated the effect of antibiotics on treatment delays, interruptions, and dose reductions in patients with mRCC treated with a first-line VEGF-TKI and presented their results at the 2018 Genitourinary Cancers Symposium.

Breast Cancer Therapies Associated With Increased Risk for Cardiovascular Disease

Breast Cancer Therapies Associated With Increased Risk for Cardiovascular Disease

By

Advances in breast cancer treatment are improving outcomes for patients with the disease; however, treatments are increasing these patients' risk for cardiovascular diseases.

Depression Predictive of Poor Survival Outcomes in Head and Neck Cancer

Depression Predictive of Poor Survival Outcomes in Head and Neck Cancer

By

In this study, researchers sought to determine the effect depressive symptoms during treatment planning had on immediate and long-term outcomes for patients with head and neck cancer.

OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer

OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer

By

In a phase 3 study presented at the 2018 Gastrointestinal Cancers Symposium, researchers reported on OS outcomes with gemcitabine plus S-1 vs gemcitabine plus cisplatin in patients with advanced biliary tract cancer.

Capecitabine and Oxaliplatin as First and Second Line Treatment for Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma

Capecitabine and Oxaliplatin as First and Second Line Treatment for Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma

[Journal of Gastrointestinal Oncology] This research evaluates the use of capecitabine and oxaliplatin (CAPOX) for first or second-line treatment of locally advanced or metastatic PDAC.

Mortality Higher in Women With Breast Cancer and Comorbid Mental Illness

Mortality Higher in Women With Breast Cancer and Comorbid Mental Illness

By

In a retrospective study of SEER-Medicare data, researchers determined the survival outcomes of women with breast cancer and comorbid mental illness vs those without mental illness.

Survival Benefit in Advanced Melanoma With Pembrolizumab Versus Ipilimumab

Survival Benefit in Advanced Melanoma With Pembrolizumab Versus Ipilimumab

By

Fifty-five percent of patients treated with pembrolizumab survived through 24-months compared with 43% of patients treated with ipilimumab.

Adjuvant Endocrine Therapy Benefits Younger Women With ER+ Breast Cancer

Adjuvant Endocrine Therapy Benefits Younger Women With ER+ Breast Cancer

By

A comparison of adjuvant endocrine therapies showed one option provided greater reduction in disease recurrence among premenopausal women with ER+ breast cancer.

Prolonging Survival in MM: Daratumumab vs Pomalidomide Plus Dexamethasone

Prolonging Survival in MM: Daratumumab vs Pomalidomide Plus Dexamethasone

By

A head-to-head comparison investigated whether patients with multiple myeloma achieved greater prolongation in overall survival with daratumumab monotherapy or pomalidomide plus low-dose dexamethasone.

Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse

Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse

By

Improved survival in pediatric patients with standard-risk ALL has shifted the focus toward reducing treatment burden and toxicity; therefore, researchers sought to determine the effects of reduced DI chemotherapy on relapse and survival.

Drug Combination Does Not Extend Glioblastoma Survival

Drug Combination Does Not Extend Glioblastoma Survival

Lomustine plus bevacizumab may increase progression-free, but not overall, survival versus lomustine alone in progressive glioblastoma.

Challenging the Standard of Care in Advanced Melanoma: Focus on Pembrolizumab

Challenging the Standard of Care in Advanced Melanoma: Focus on Pembrolizumab

[Cancer Management and Research] This study examines the advances that pembrolizumab has made in melanoma and upcoming research that may further improve melanoma treatment.

Outcomes Best With Discharge to Home vs PAC or Hospice in Advanced Cancer

Outcomes Best With Discharge to Home vs PAC or Hospice in Advanced Cancer

By

In a prospective study, researchers assessed survival and quality of life measures for patients with advanced cancer in relation to where they are discharged from hospital: postacute care (PAC), hospice, or home without hospice.

Oncologists, Patients Have Different Views on AML Treatment Outcomes, Prognosis

Oncologists, Patients Have Different Views on AML Treatment Outcomes, Prognosis

By

Comparison study via questionnaires assessed patients' and oncologists' views on likelihood of dying as a result of treatment shortly after beginning intensive or nonintensive chemotherapy for AML, and their views on prognosis 1 month later.

Carfilzomib Administered Once Weekly Prolongs PFS in Multiple Myeloma

Carfilzomib Administered Once Weekly Prolongs PFS in Multiple Myeloma

By

Researchers randomly assigned 478 patients with R/R MM to receive carfilzomib 70 mg/m2 once weekly plus dexamethasone or carfilzomib 27 mg/m2 twice weekly plus dexamethasone.

All-Cause Mortality Improved by Advances in Radiotherapy for Hodgkin Lymphoma

All-Cause Mortality Improved by Advances in Radiotherapy for Hodgkin Lymphoma

By

Investigators assessed the impact of advances over time in the treatment of Hodgkin lymphoma on all-cause mortality in patients with Hodgkin lymphoma who received radiotherapy alone or with chemotherapy.

Dapsone, Danazol, Hydroxychloroquine Are Potential Second-line Options in ITP

Dapsone, Danazol, Hydroxychloroquine Are Potential Second-line Options in ITP

By

A retrospective analysis of 28 studies determined that overall response rates for patients with ITP were similar treated with hydroxychloroquine, danazol, or dapsone in the second-line setting were similar.

Radiation Prior to Chemotherapy Prolongs Progression-Free Survival in NSCLC

Radiation Prior to Chemotherapy Prolongs Progression-Free Survival in NSCLC

By

Researchers present findings of a phase 2 study that compared PFS when SBRT is administered prior to maintenance chemotherapy in patients with limited metastatic NSCLC vs chemotherapy alone. Data was presented at ASTRO 59th Annual Meeting.

Severe Mental Illness May Worsen Breast Cancer Survival Outcomes

Severe Mental Illness May Worsen Breast Cancer Survival Outcomes

By

Retrospective analysis of data from more than 19,000 women revealed that all-cause mortality rates are higher in women with breast cancer who have a prior diagnosis of a mental illness.

Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination

Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination

By

Overall survival was significantly prolonged in patients with advanced melanoma who were treated with nivolumab plus ipilimumab compared with either drug alone, according to results from the Checkmate 067 study.

Progression-Free Survival in CLL Prolonged With Maintenance Lenalidomide

Progression-Free Survival in CLL Prolonged With Maintenance Lenalidomide

By

Lenalidomide reduced the relative risk of disease progression in a clinical trial of patients with chronic lymphocytic leukemia who did not achieve MRD negative disease state after first-line chemoimmunotherapy.

Progression-Free, Overall Survival in Liposarcoma Improved With Eribulin vs Dacarbazine

Progression-Free, Overall Survival in Liposarcoma Improved With Eribulin vs Dacarbazine

By

Comparison study shows significantly improved overall survival and progression-free survival in patients with advanced LPS treated with eribulin vs dacarbazine.

Reduced-Dose Sorafenib Effective and Economical in Hepatocellular Carcinoma

Reduced-Dose Sorafenib Effective and Economical in Hepatocellular Carcinoma

By

Reducing the initial dose of sorafenib was shown to have some benefits — such as reduced pill burden, lower costs, and decreased AE-related discontinuation rates — and OS was noninferior compared with the standard dose in patients with hepatocellular carcinoma.

Carfilzomib Improves Overall Survival in Relapsed/Refractory Multiple Myeloma

Carfilzomib Improves Overall Survival in Relapsed/Refractory Multiple Myeloma

By

The first interim analysis of the ENDEAVOR trial reported superiority of carfilzomib in some outcomes; however, data on overall survival were not available. This second interim analysis reports on overall survival with carfilzomib for patients with relapsed/refractory multiple myeloma.

Hospital Volume, Quality Impact Survival in Ovarian Cancer

Hospital Volume, Quality Impact Survival in Ovarian Cancer

Survival rate were worse for lower volume hospitals with higher quality scores, versus higher volume hospitals.

Decitabine Improves Overall Survival, Overall Response Rate in Chronic Myelomonocytic Leukemia

Decitabine Improves Overall Survival, Overall Response Rate in Chronic Myelomonocytic Leukemia

By

Patients with high-risk chronic myelomonocytic leukemia (CMML), a MDS/myeloproliferative neoplasm, may experience prolonged overall survival and increased overall response rate from treatment with decitabine.

Survival Predictions for NSCLC Accurate With the Lung Cancer Prognostic Index

Survival Predictions for NSCLC Accurate With the Lung Cancer Prognostic Index

By

The Lung Cancer Prognostic Index (LCPI) provides additional relevant prognostic data for patients with NSCL and may lead to better outcomes.

Rare Case of Langerhans Cell Histiocytosis With Prior ITP Highlights Diagnostic Challenge for Clinicians

Rare Case of Langerhans Cell Histiocytosis With Prior ITP Highlights Diagnostic Challenge for Clinicians

By

A rare case of Langerhans cell histiocytosis (LCH) in a patient with idiopathic thrombocytopenic purpura (ITP) highlights the difficulty in diagnosing LCH.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs